Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating 89bio for potential breaches of fiduciary duty and other legal violations related to its transaction with Roche [1] Group 1 - 89bio shareholders will receive $14.50 per share in cash at closing [1] - Shareholders will also receive a non-tradeable contingent value right (CVR) for certain milestone payments [1]